Leading investments in innovative biotechnology and healthcare companies. Focusing on long term investing out of a $8Bn AUM hedge fund to support companies through their entire life cycle (from early through crossover and public stages).

Investing in early stage ventures at the frontier of biotech and engineering in therapeutics, diagnostics and tools.Seed and Series A Lead investments include Scribe Therapeutics, Insitro, Genesis Therapeutics, EQRx, Octant Biosciences, Tmunity, Nautilus, Earli, and several stealth seeds in the biotech space.

Engineering molecular technologies to precisely edit the genome and developing a next-generation sequencing platform to quantify the molecular "age" (therefore health) of a cell.· Developing and applying CRISPR/Cas9 system for precise, targeted re-activation of genes (TERT, TFAM, GDF-11, NAMPT) normally down-regulated during senescence for the development of age reversal and cancer therapies.· Developing a next-generation sequencing platform of key CpG sites to analyze methylation and other epigenetic features in order to (1) establish a panel of diagnostic aging biomarkers and (2) using that information to generate an algorithm or quantitative model that can calculate the molecular “age” of the cell.· Synthesized Adeno-associated virus (AAV) vectors for delivery of CRISPR Cas9 constructs into mice for in vivo testing of activators.· Designed and engineered a photo-activated CRISPR/Cas9 construct that allows high-resolution spatial and temporal precision in human genome engineering upon light stimulus.

Implemented a high-throughput screening of >10,000 cancer target loci in a class of protein. My research led to the discovery of 3 new cancer drug targets. Targets approved for further in vivo testing.

I edit incoming publications on the IEEE journal related to a range of clinical and translational research in biotech. I also write analytical blog posts on the journal website to draw attention to highly trending research concepts and to promote discussion about various potentially high-impact technologies.

Designed and implemented an agarose bead-based microarray within a microfluidic platform that rapidly captures and detects various key biomarkers of cardiovascular disease and cancer via micro-sandwich immunoassay. · CAD designed via Solidworks and rapid prototyped multiple iterations of a self-contained microfluidic chip via xurography and photolithography.· Chemically synthesized three-dimensional agarose microbeads for anchoring and concentrating capturing antibodies for the specific fluorescent detection of cTnI, CK-MB, myoglobin, NT-proBNP (specific biochemical markers of cardiovascular disease) and CA-125(ovarian cancer biomarker).Ultimately, developed a sensor with limits of detection that meets clinical cut-off values for key biomarkers in sub-15 minutes time with less than 100uL of blood--thereby producing a rapid point-of-care diagnosis for a range of cardiac diseases and cancers.· The system was verified with 200 clinical patient samples of a range of cardiovascular health and accuracy/limits of detection compared successfully(R2=99.2%) against gold standard ELISA systems and commercial machines.· By chemically modifying antibody and micro-bead synthesis and optimizing optics detection software, the platform can be reprogrammed to detect any known biomarker, potentially allowing the device to be a universal, point-of-care disease detection platform.

Designed and synthesized chitosan nanoparticles, a low cytotoxicity, biodegradable, and PEGylated drug vector used to selectively deliver si-RNA molecules to ovarian cancer cells while evading the host’s immune system.· Used confocal laser scanning microscopy and fluorescence activated cell sorting to detect and quantify targeted intracellular uptake of nanoparticles in cancer cells.· Conducted live-cell imaging assays to track and analyze the trajectory of particles to understand the intracellular transport mechanisms of si-RNA nanoparticles in cancer cells.· Conducted a comprehensive array of in vitro assays manipulating the biochemical environment of the cells to determine the clinical efficacy of the nanoparticles in a protein-rich environment such as the blood. SDS-PAGE analysis was also conducted to determine if any key proteins inhibited the nanotherapeutic’s efficacy.